Topic: targeted therapies
Several cancer drug candidates are designed to kill tumor cells by attacking certain targets, but they work in other ways, researchers found.
Amgen unveiled data for the highest dose of its KRAS inhibitor, showing it kept cancer at bay in 100% of lung cancer patients.
After one year, 14 out of 16 treated lesions tested negative for signs of cancer, according to procedure developer Nanospectra Biosciences.
José Baselga, AstraZeneca's R&D chief, discussed capivasertib, how to pick the best drug for patients and what needs to change before cancer is cured.
It’s been 30 years in the making, but the first clinical data from a KRAS inhibitor is finally here.
A Boston University-led team found a novel activator of NRAS and developed a small molecule to inhibit the growth of NRAS-mutant melanoma.
Early data showed that Blueprint's RET inhibitor and AstraZeneca’s Tagrisso could potentially beat treatment resistance in NSCLC patients.
SpringWorks Therapeutics named its first CEO and unveiled a partnership with BeiGene around a combination therapy for RAS-mutated cancers.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
A stem cell pathway could be targeted to create more effective treatments for triple-negative breast cancer.